James Linder, MD
Ophthalmology · Marion, ARNPI 1578640660
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,690 of the $17,782 with a category attached, or 77.0%. Amgen accounts for 80.0% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2021 at $6,500 and has fallen 93.9% since, to $394 in 2025. Among ophthalmology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $177.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$14K
- Merz North America, Inc.$2K
- Katena Products, Inc. (dba Corza Medical)$1K
- AbbVie$177
- Revance Therapeutics, Inc.$148
- Genentech USA, Inc.$104
- plus $326 from 12 others
What the payments were for
- Royalty or licence$6494%
- Speaking & faculty fees$13,69077%
- Food & beverage$3,44319%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 56 | $14,234 |
| Merz North America, Inc. | 10 | $1,791 |
| Katena Products, Inc. (dba Corza Medical) | 8 | $1,003 |
| AbbVie(2 entities) | 4 | $177 |
| Revance Therapeutics, Inc. | 1 | $148 |
| Genentech USA, Inc. | 4 | $104 |
| Kowa Pharmaceuticals America, Inc. | 4 | $87 |
| Biotissue Holdings Inc. | 2 | $36 |
| Eyevance Pharmaceuticals LLC | 2 | $36 |
| Johnson & Johnson | 1 | $25 |
| Novartis | 1 | $23 |
| Organogenesis Inc. | 1 | $22 |
| Teleflex LLC | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Avanos Medical | 1 | $18 |
| Heron Therapeutics, Inc. | 1 | $15 |
| UCB, Inc. | 1 | $14 |
| Kala Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,782 in reported general payments places this provider in the 95th percentile of 125 ophthalmology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 11 | $7,106 |
| Fluorometholone | 83 | $5,078 |
| ErythromycinErythromycin Base | 207 | $2,143 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 108 | $1,186 |
| Latanoprost | 80 | $629 |
| Ofloxacin | 30 | $331 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 20 | $249 |
| Doxycycline Hyclate | 18 | $190 |
| Tramadol Hcl | 26 | $55 |
| Clonazepam | 12 | $12 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $177 | $7,10611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 125 ophthalmology providers in Arkansas.
Other ophthalmology in Marion
- Daniel SinesRogers$81K
- Mike McFarlandPine Bluff$63K
- Jennifer DoyleLittle Rock$38K
- Matthew MargolisJonesboro$17K
- Thomas StankJonesboro$16K
- Andrew PerinNorth Little Rock$4K
- Jeffrey HoltHot Springs$4K
- Joshua LittleJonesboro$4K
- Jonathan CascianoLittle Rock$4K
- Christian HesterLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.